This course has expired. View available courses.
Endocrinology, Medication Management
DPP-4 inhibitors for Type 2 Diabetes. Who, when, and why? – ACRRM
Medical treatment of Type 2 Diabetes (T2D) has become increasingly complex, as new classes of hypoglycaemic medications are developed and clinical guidelines are updated to reflect these developments. DPP4is are a useful addition to many T2D treatment plans, especially for complex patients with comorbidities that limit the use of other drug classes. Upon completion of […]
DURATION
1 hr
PROFESSION
Physician
# OF CREDITS
1
ACCREDITATION
ADEA, ACRRM
EXPIRY DATE
2022-12-31
Medical treatment of Type 2 Diabetes (T2D) has become increasingly complex, as new classes of hypoglycaemic medications are developed and clinical guidelines are updated to reflect these developments.
DPP4is are a useful addition to many T2D treatment plans, especially for complex patients with comorbidities that limit the use of other drug classes.
Upon completion of this program, you will be able to confidently identify patient groups likely to benefit from DPP4is, and have the knowledge to appropriately prescribe DPP4is.
This program was developed by MDBriefcase, and funding provided by Boehringer Ingelheim.
Faculty
Anita Sharma, General Practitioner, Queensland (QLD)
Tom Dover, Endocrinologist, Queensland (QLD)
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Review the use of DPP4is for patients with T2D in line with current guidelines
- Identify patients for whom DPP4is are indicated and a good option from a clinical, practical and treatment goal perspective.
- Determine when a DPP4i is an appropriate option as dual therapy or subsequent medication to reach individualised diabetes treatment goals.
- Overcome clinician-mediated and patient-mediated clinical inertia to initiate timely escalation of diabetes treatment, with the aim of reaching glycaemic targets, improving medication adherence and considering patients’ preferences.
- Confidently discuss with patients a DPP4i option, including counselling on the advantages and disadvantages of changing their medication in order to achieve a better clinical outcome.
Accreditation
This PDP Activity is accredited by The Australian College of Rural & Remote Medicine for 1 hour of Educational Activity.
ACRRM ID: 24731
This course is endorsed and accredited by the ADEA for 1 CPD point.